Margin of Safety

At about $44, Cognizant's roughly $19.5 billion enterprise value capitalizes its free cash flow at more than 12%. Discounted at a 10% cost of equity, that price embeds a perpetual decline of about 2% in free cash flow. Four independent methods put fair value near $60–68, over a no-growth floor of roughly $55. So a margin of safety exists — but it is moderate, not table-pounding, and it is most sensitive to whether the cash-flow base holds.

What $44 buys

What an owner actually buys at $44 is worth spelling out. Cognizant guides to about 473 million shares for 2026 [1], a roughly $20.8 billion equity value. Against that sits a net-cash balance sheet — $1,901 million of cash and $13 million of short-term investments versus $33 million of short-term and $543 million of long-term debt at year-end 2025 [2], or about $1.34 billion of net cash. Enterprise value is therefore near $19.5 billion.

The cash flow that value claims is substantial and steady. Cognizant generated $2,883 million of operating cash flow in 2025 against $288 million of capital spending [3] — about $2.6 billion of free cash flow, and a five-year average near $2.2 billion. Cash Conversion established that this converts net income at a durable ~1.1x once one-off tax items are removed, so the free-cash-flow base is real rather than an accrual artefact.

Share price and mean analyst target from market data, as reported (price July 17, 2026; consensus as of July 17, 2026). Forward P/E on 2026 adjusted-EPS guidance of $5.63–5.77 [4]; FCF yield and EV/FCF on normalized free cash flow of ~$2.4 billion derived from the FY2025 cash-flow statement [5].

At 7.7 times forward earnings and roughly eight times free cash flow, the multiple is undemanding on its face. The number is plainly low; what matters is the future it discounts.

The growth the market has priced out

A reverse discounted-cash-flow test answers that directly. Hold enterprise value at $19.5 billion, use a 10% cost of equity — reasonable for a business with no net debt, low capital intensity, and a globally diversified client base — and solve for the perpetual free-cash-flow growth rate the price implies. On normalized free cash flow of about $2.4 billion, that rate is roughly negative 2%. On 2025's actual $2.6 billion, it is more negative still.

Implied perpetual growth solving EV = FCF ÷ (r − g) at EV ≈ $19.5B and normalized FCF ≈ $2.4B; balance-sheet and cash-flow inputs from the FY2025 10-K [6].

Whichever discount rate one prefers, the market is not pricing stagnation — it is pricing a slow, permanent shrinkage of the free-cash-flow base. Cognizant's ~$19.5B enterprise value on ~$2.4B normalized free cash flow at a 10% cost of equity implies roughly -2% perpetual FCF growth against guided +4% to +6.5% constant-currency revenue, yet every one of its six named peers fell 26% to 48% over the same window (Accenture worst at -48% vs CTSH -47%) while Cognizant's own organic constant-currency growth cooled to ~2.9% on flat annual contract value — so the market is pricing an industry-wide, not company-specific, secular decline. That framing is worth dwelling on, because it is exactly the opposite of what the company and the sell-side expect. Management's own 2026 guidance is 4.0%–6.5% constant-currency revenue growth and 7%–9% adjusted-EPS growth [7]; consensus carries $5.69 in FY2026 earnings rising to $6.18 in FY2027, mid-single-digit revenue growth throughout. The gap between "grows a few percent" and "declines a few percent forever" is what the investment case turns on, and it is what The Nonlinearity Test was built to adjudicate: that chapter's read was that generative AI is bending the headcount-to-revenue link, not breaking it.

Triangulating fair value

No single model settles a valuation, so it is worth seeing where independent lenses land. Four of them cluster.

No-growth capitalization and DCF built on normalized FCF (~$2.4B) and net cash (~$1.34B) from the FY2025 10-K [8]; forward-earnings multiples on 2026 adjusted-EPS guidance [9]; mean target from market data, as reported.

The no-growth floor is the most important number for this reader. Capitalize $2.4 billion of free cash flow at a 10% required return and add net cash, and the business is worth about $55 a share assuming it never grows again. At $44 the stock trades roughly 20% below that floor — meaning the buyer is paid to hold a business the market assumes is in terminal decline, and gets any growth for free. The June 2026 low of $38.73, noted in Business and Derating, was about 30% below the no-growth value: for a few weeks the market priced not merely no growth but active erosion.

The other three lenses converge near $60–68. Notably, the sell-side mean target of $64 is not a heroic call — it implies roughly 11 times forward earnings and about 2% of embedded growth. The upside to that consensus is a re-rating story, not a growth story: the multiple need only normalize from eight times toward a still-cheap eleven for the stock to reach the mid-$60s. That is a lower bar than betting on accelerating revenue.

The margin of safety and its condition

For a value investor demanding a margin of safety, the arithmetic is favorable but not overwhelming. Against a triangulated fair value near $64, the ~$44 price offers roughly 45% upside; against the harsher no-growth floor of ~$55, about 25%. Two structural features harden the downside. First, the balance sheet: $1.34 billion of net cash is a real, if modest, cushion — about $2.80 a share — and it removes the bankruptcy risk this reader excludes outright, since a business with more cash than debt and $2.6 billion of annual free cash flow does not fail. Second, the mechanics of the buyback: with the board having doubled the 2026 repurchase target to $2 billion and left about $3.45 billion authorized [10], a fixed-dollar program retires far more stock at $44 than at $75, quietly compounding per-share value for a non-seller — the argument Capital Allocation developed in full.

But the margin of safety depends above all on the free-cash-flow base not eroding. Every fair-value estimate above starts from ~$2.4 billion of durable free cash flow. If generative AI genuinely compresses labor-arbitrage economics — if the ~50% fixed-bid book reprices, or pricing-per-person deflates — then the "no-growth floor" is not a floor at all, and the market's implied −2% could prove generous rather than fearful. That is the honest counter-case, and it is not idle: Standing Among Peers showed the entire sector re-rated 26%–48% in 2026, so the market is discounting a real, industry-wide risk, not a company-specific panic. The valuation does not resolve that debate; it prices it. What the low multiple does is change the odds — at eight times free cash flow, the model has to actually shrink, not merely stop growing, before a buyer at $44 loses money.

That is the shape of the setup this reader looks for: near-term pain already inflicted, a cheap price, a clean balance sheet, and a clear condition — free-cash-flow durability — whose resolution over the next few prints decides whether the ~$55 floor holds or gives way.

What would change the read

Two observations would firm up the case: organic revenue (ex-Belcan and the cloud acquisitions) holding at or above the low-single digits, and realized margins on the fixed-bid book tracking plan through 2026 — the falsification test flagged in The Nonlinearity Test. Two would break it: a sequential decline in free cash flow that is not explained by working-capital timing, or evidence that pricing per delivered outcome is deflating as AI tooling spreads. The valuation is cheap enough to be interesting and cushioned enough to be safe-ish; whether it is cheap enough to be a margin of safety depends on which of those the next few quarters show.